ABL1 Gene Kinase Domain Mutation Analysis (Gleevec resistance)
Tyrosine kinase inhibitors such as Gleevec (AKA Imatinib) are effective drugs to treat t(9:22) positive CML and ALL. However, drug resistance may occur during the course of treatment due to the development of mutations in the kinase domain of ABL1 gene. Early detection of these mutations may prevent clinical relapse and allow the use of alternative tyrosine kinase inhibitors.
Indications for Testing:
- Concern about possible failure to respond to Imatinib (Gleevec)
- Significant increase in the Quantitative BCR/ABL
2-3 mL whole blood or bone marrow in purple top EDTA tube
Sample should be kept cold, never frozen. This test is RNA based. RNA is very delicate and easily degraded. Do not delay in shipping as delay may affect results. For optimal results, fresh specimens should be shipped on the day of collection. Refrigerate specimens if held overnight.
Specimens being sent from outside facilities should be packaged according to standard medical safety practices. The specimen should be shipped by overnight priority [scheduled to arrive by Friday AM at the latest]. Use cold pack for overnight transport. Be sure cold pack is not in direct contact with specimen during transport.
Center for Human Genetics Laboratory
10524 Euclid Ave, 6th Floor
Cleveland, OH 44106
For local samples, please call Client Service (216-844-5227) to arrange for sample pick-up.
Turn Around Time:
Please submit a completed Hematology/Oncology Specimens requisition for each sample.